Clinical Trial Update: Selvigaltin With Standard of Care Treatment for the Treatment of Relapsed/Refractory Multiple Myeloma [Phase 1]

View source ↗

Summary

A Phase 1 trial of Selvigaltin in combination with standard of care for relapsed/refractory multiple myeloma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Selvigaltin (Selvigaltin)

Snippet

Sponsor: Roswell Park Cancer Institute | Conditions: Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 | Status: WITHDRAWN